AngioDynamics Q3 FY2026: Med Tech sales up 19%, raises full-year guidance

ANGIODYNAMICS INC

2026-Q3 EPS reported -$0.61 revenue$233,567,000

Net sales $78.4M (+8.9% pro forma); Med Tech $37.3M (+19%) driven by Auryon, thrombectomy, NanoKnife.
GAAP net loss $8.1M (-$0.19/shr); adjusted EBITDA $1.8M vs $1.3M prior year.
Raised FY2026 net sales guidance to $313.5-315.5M; adjusted EBITDA now $10-12M (prev $8-10M).
Tariff impact $1.3M in Q3; full-year tariff expectation unchanged at $4-6M.
Cash $37.8M, debt-free; expects Q4 cash flow slightly negative due to $3-5M inventory build for sterilization shutdowns.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ANGIODYNAMICS INC reported third quarter of fiscal year 2026 ended February 28, 2026 results: revenue $78.4 million. Guidance raised.

Period: third quarter of fiscal year 2026 ended February 28, 2026
Revenue: $78.4 million
Guidance: raised
Result: reported results

Exact text from the filing

the third quarter of fiscal year 2026, which ended February 28, 2026. Fiscal Year 2026 Third Quarter Highlights Quarter Ended February 28, 2026 Pro Forma* YoY Growth Net Sales $78.4 million 8.9% Med Tech Net Sales $37.3 million 19.0% Med Device Net Sales $41.1 million 1.1% • GAAP gross margin of 52.9% • GAAP loss per share of $0.19 • Adjusted loss per share of $0.07

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

ANGIODYNAMICS INC filing history →

Source: SEC EDGAR

accession 0001140361-26-012891

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.